Abivax S.A.
ABVX scores 22.1 on the Aggressive profile, blending a fundamental score (55% weight, emphasizing growth and momentum (91% of fundamental weight)) with a machine-learning signal (45% weight) trained on 82 features across 30 years of data.
Net penalties of -23.4 points significantly impact the ranking. Without these adjustments, ABVX would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| ABVX | 22.1 | N/A | 133.5% | -3244.0% | $8.5B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $20.1B |
| GMAB | 85.5 | 13.1 | 22.8% | 36.4% | $18.5B |
| CPRX | 82.2 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $126.0B |
| ASND | 75.7 | 16.6 | 98.0% | -31.7% | $13.3B |
| NBIX | 74.7 | 26.5 | 21.4% | 16.7% | $12.5B |
| ALKS | 74.6 | 16.5 | -6.4% | 23.9% | $5.5B |
| AMGN | 73.8 | 26.0 | 10.0% | 21.0% | $199.0B |
| ARGX | 73.6 | 35.1 | 78.6% | 38.0% | $50.9B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.7 | 19.4 | 1.0% | 31.4% | $84.9B |
| ISRG | 72.3 | 61.7 | 20.5% | 28.4% | $172.5B |
| EXEL | 71.9 | 15.1 | 7.0% | 33.7% | $11.7B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $8.0B |
| HALO | 70.2 | 16.8 | 22.4% | 43.7% | $9.3B |
| Sector Average | 37.1 | 252.3 | 161.5% | -3292.7% | — |
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $2M | $7M | $3M | $2M |
| Gross Profit | $2M | $7M | $3M | $2M |
| Operating Income | $-94M | $-133M | $-40M | $-92M |
| Net Income | $-101M | $-95M | $-41M | $-96M |
| EPS (Diluted) | $-1.59 | $-1.50 | $-0.65 | $-1.98 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -4645.3% | -1797.3% | -1178.9% | -3975.2% |
| Net Margin | -4996.7% | -1278.6% | -1203.0% | -4118.1% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2024 | $6.53 | $17.02 | 89.1% | Wide |
| 2025 | $4.77 | $148.83 | 187.6% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.